Case report demonstrates tumor regression in advanced endometrial cancer, suggesting a promising treatment strategy.
Lenvatinib plus pembrolizumab may represent a feasible neoadjuvant option for achieving tumor regression and enabling surgical resection with a pathological complete response in advanced endometrial cancer.
No takes yet. Share an insight, caveat, or question.
Konnai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: